The abstract is read at the publisher; the summary is JClub's.
CDK12-knockout prostate cancer cells show an ATM-like DSB response phenotype and are sensitized to ATR inhibition, with combined PARP plus ATR suppressing growth in CDK12-defective patient-derived xenografts.
- Why it matters: CDK12-altered prostate cancers are aggressive and often show limited benefit from PARP inhibitor monotherapy, so the functional impact of CDK12 loss and a rational combination therapy are needed.
- What they did: Using CRISPR/Cas9 to generate CDK12-knockout prostate cancer cell lines, the study measured cell-cycle control, DNA damage via γH2AX immunofluorescence, and replication stress with flow cytometry and DNA fiber assays, then tested PARP plus ATR in patient-derived xenograft models.
- The result: CDK12 loss abrogated the G0-G1 checkpoint, increased intrinsic replication stress, and reduced ATM transcription, while dual PARP and ATR inhibition increased DSB accumulation and selectively suppressed tumor growth in CDK12-defective models.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.